Domainex moves to new research building in Cambridge, UK

To support the expansion of its drug discovery service business

Domainex, a small molecule drug discovery company, is expanding all aspects of its business and has signed a long-term lease with Aviva Investors for a laboratory building at Chesterford Research Park, Cambridge, UK to accommodate this growth.

The two firms say they plan to invest 'several million pounds' in the new building, which will increase capacity by 140%.

Eddy Littler, Chief Executive of Domainex, said: 'We are delighted with the growth our service business has achieved over the last few years, and this year we anticipate further expansion across the range of our biology and chemistry service offerings. We are in the middle of a significant recruitment round in which we have brought a number of excellent scientists into the company.'

The next step in the firm's expansion is moving to the new 20,000ft2 laboratory in Summer 2016.

Keith Powell, Chairman of Domainex, added: 'As evidenced by our recent announcements regarding our contracts with Imperial College and Auspherix, we are continuing to develop Domainex as a high-quality research company capable of first-in-class protein expression, biochemistry, cell biology and computational and medicinal chemistry. Putting this growth alongside our successful in-house programmes on epigenetic targets, the need for expansion space is evident; we are delighted to have found this solution at Chesterfield Research Park.'